The Tc-99m used in MBI is byproduct material regulated by the NRC under 10 CFR Part 35 for medical use and 10 CFR Part 20 for radiation protection, or by the equivalent Agreement State program. The imaging device itself is a gamma camera, not an X-ray machine, so it is not under MQSA — though breast-density notification rules still shape when supplemental imaging is discussed.

Molecular Breast Imaging: CZT Cameras & Dose

Q: Why is a CZT detector used for MBI?

Cadmium zinc telluride (CZT) is a direct-conversion semiconductor detector that converts gamma rays straight into an electrical signal, giving better energy resolution and a compact pixelated design than a conventional NaI(Tl) Anger camera. Better energy resolution improves scatter rejection, and the small pixel size supports the high spatial resolution needed to detect sub-centimeter breast lesions.

Q: Does MBI help in dense breasts?

Yes. In women with mammographically dense breasts, adding MBI to screening mammography has been shown to substantially increase the cancer detection rate — a reported supplemental yield of about 8.8 additional cancers per 1,000 women screened in one large study — because functional uptake is not masked by dense tissue the way anatomic lesions are on mammography.

Q: Is MBI the same as breast-specific gamma imaging (BSGI)?

They are closely related. Both use Tc-99m sestamibi and a dedicated gamma camera to image tumor uptake. MBI most commonly refers to dual-head, direct-conversion CZT systems developed for reduced-dose imaging, while breast-specific gamma imaging historically referred to single-head systems. The clinical principle — functional tumor imaging independent of density — is the same.

Q: What quality control does an MBI system need?

An MBI gamma camera needs routine QC analogous to any gamma camera: energy-peak and window verification, uniformity, spatial resolution, sensitivity, and count-rate checks, along with dose-calibrator QC for the administered activity. A qualified medical physicist establishes and reviews this program and confirms detector performance.

Molecular breast imaging (MBI) detects breast cancer by imaging function, not anatomy: it maps the preferential uptake of Tc-99m sestamibi in tumor tissue with a dedicated cadmium-zinc-telluride gamma camera. Because it is blind to fibroglandular density, it adds real cancer detection in women whose dense breasts limit mammography — but only because detector physics, collimator design, and dose reduction were engineered to make it a screening-acceptable exam.

Introduction

Mammography is the backbone of breast cancer screening, but its sensitivity falls in dense breasts, where overlapping fibroglandular tissue can both hide tumors and mimic them. Roughly 40–50% of screening-age women have dense breasts, and dense tissue is itself an independent risk factor. That gap is what supplemental modalities — ultrasound, MRI, and molecular breast imaging — are designed to fill. ¹³

MBI takes a fundamentally different approach from any anatomic modality. Instead of looking for a mass, it images metabolism: malignant cells concentrate the radiotracer Tc-99m sestamibi, and a gamma camera positioned against the lightly compressed breast detects that uptake as a focus of increased signal. Dense tissue does not mask a functional signal the way it masks an anatomic one, which is why MBI's performance is largely independent of breast density. ³⁴

The reason MBI is clinically usable today — rather than a high-dose research curiosity — is a chain of physics advances: direct-conversion CZT detectors, collimation optimized for the imaging geometry, and the resulting ability to cut administered activity to a screening-acceptable level. ⁴⁵ This article explains how MBI works, the detector and collimator physics behind it, its radiation dose, its clinical role in dense breasts, the QC it requires, and its regulatory context. DRPS supports MBI and dedicated nuclear-imaging programs through its PET/CT and nuclear medicine physics services.

Topic Explanation

What is molecular breast imaging?

Molecular breast imaging is a functional nuclear medicine exam in which a patient is injected with Tc-99m sestamibi and imaged with a dedicated small-field-of-view gamma camera, with the breast under light compression. Tumors preferentially retain sestamibi — the same tracer used in cardiac and parathyroid imaging — because of their increased mitochondrial activity and blood flow, so cancers appear as focal areas of increased radiotracer uptake against the lower background of normal tissue. ⁴⁶

Standard imaging uses a dual-head configuration, with a detector above and below the compressed breast, in craniocaudal and mediolateral oblique views mirroring mammographic positioning. Because it images uptake, MBI reports background parenchymal uptake (BPU), which is itself an emerging risk marker independent of mammographic density. ⁶

Related terms

Tc-99m sestamibi — the lipophilic cationic radiopharmaceutical that concentrates in metabolically active tissue, including many breast cancers. ⁴
CZT (cadmium zinc telluride) — a direct-conversion semiconductor detector material used in modern MBI cameras. ⁴⁵
Breast-specific gamma imaging (BSGI) — a closely related term, historically for single-head dedicated gamma cameras.
Background parenchymal uptake (BPU) — the normal-tissue radiotracer uptake on MBI, associated with breast cancer risk. ⁶
Supplemental yield — the number of additional cancers detected per 1,000 women when a modality is added to mammography. ¹

For the shared instrumentation background, see our guides to gamma camera collimator selection and gamma camera uniformity QC.

Key Technical Principles

Why CZT changed dedicated breast imaging

A conventional Anger camera detects gamma rays with a NaI(Tl) scintillator coupled to photomultiplier tubes: the gamma ray makes light, the light makes an electrical signal, and position is inferred from the pattern of tube outputs. A CZT detector is a direct-conversion semiconductor — the gamma ray produces electron-hole pairs directly in a pixelated crystal, skipping the light-conversion step. The practical consequences matter for breast imaging: ⁴⁵

Property	NaI(Tl) Anger camera	CZT direct-conversion
Detection mechanism	Scintillation light → PMT	Direct charge collection
Energy resolution at 140 keV	~9–10%	~5–6%
Intrinsic spatial resolution	Limited by light spread	Set by pixel pitch (~1.6–2.5 mm)
Detector profile	Bulky (PMTs)	Compact, flat
Energy windowing	Symmetric photopeak window	CZT-optimized acceptance window

Better energy resolution gives the CZT camera a well-defined 140 keV photopeak, and its response can be paired with an energy acceptance window optimized for the detector rather than a generic symmetric window. In reduced-dose MBI, that optimized window is deliberately widened and shaped to recapture the CZT low-energy tail (from incomplete charge collection), which raises count sensitivity — a different goal from simple scatter rejection. ⁴⁵¹² The compact, pixelated geometry also lets the detector sit close to the breast in a dual-head design, which raises geometric efficiency. Both effects are exactly what small-lesion detection needs. ³⁴

Collimation, resolution, and the sensitivity trade-off

Like any gamma camera, an MBI system's spatial resolution and sensitivity are governed by the collimator, and the two trade against each other. For a parallel-hole collimator with hole diameter $d$ , effective hole length $l_{eff}$ , and a source at distance $b$ from the collimator face, the system spatial resolution contributed by the collimator is approximately:

R_{c} \approx d \cdot \frac{l _{eff} + b}{l _{eff}}

and the geometric (sensitivity) efficiency scales as:

g \propto (\frac{d ^{2}}{l _{eff} ( d + t )})^{2}

where $t$ is the septal thickness. These equations capture the central tension: shrinking the hole diameter $d$ or lengthening the holes sharpens resolution ( $R_{c}$ smaller) but reduces sensitivity ( $g$ smaller), forcing either more activity or longer imaging times.

The breakthrough for reduced-dose MBI was to optimize the collimator specifically for the MBI geometry rather than borrow a general-purpose design. Weinmann, Hruska, and O'Connor showed that square-hole collimators matched to the CZT pixel pitch could improve collimator sensitivity by factors of roughly 1.5–3.2 while holding resolution adequate to detect sub-10 mm lesions. ⁵ Combined with a CZT-optimized energy window, these count-sensitivity improvements were validated in patients: low-dose MBI at 296 MBq achieved a relative count-density gain of about 4.2× over the legacy 740 MBq technique while preserving detection of small lesions. ¹² Because dose scales inversely with sensitivity for a fixed image quality, that sensitivity gain translated almost directly into a proportional reduction in the activity required. ⁵¹²

Administered activity and effective dose

The patient dose in MBI is set by the administered activity of Tc-99m sestamibi and the tracer's dose coefficient. Effective dose is estimated as:

E = A \cdot e

where $A$ is the administered activity and $e$ is the effective dose coefficient for Tc-99m sestamibi (on the order of $9 \times 1 0^{- 3} mSv/MBq$ for a resting administration). For a low-dose screening protocol using $A = 300 MBq$ :

E \approx 300 MBq \times 9 \times 1 0^{- 3} mSv/MBq \approx 2.7 mSv

The large prospective dense-breast screening trial by Rhodes and colleagues used 300 MBq and reported an effective dose of about 2.4 mSv for the exam. ¹ Earlier MBI systems used administered activities two to three times higher — roughly 7–10 times the dose of screening mammography — and it was precisely the detector and collimator optimization that permitted the drop to this screening-acceptable range. ⁵

Clinical Impact

MBI's defining clinical result is its supplemental cancer detection in dense breasts. In the Rhodes prospective study of 1,585 women with mammographically dense breasts and a complete reference standard, adding MBI to screening mammography raised the overall cancer detection rate from 3.2 to 12.0 per 1,000 screened — a supplemental yield of 8.8 additional cancers per 1,000 women — and increased the invasive cancer detection rate from 1.9 to 8.8 per 1,000. Sensitivity for the combination rose to 91%, versus 24% for mammography alone in this dense-breast population. ¹

That yield comes with the usual supplemental-screening cost: more recalls and more biopsies. In the same program, recall rate rose from 11.0% to 17.6% and the biopsy rate from 1.3% to 4.2% when MBI was added. A companion cost analysis found that although MBI increased the cost per patient screened, the cost per cancer detected was actually lower for the combination than for mammography alone, because of the higher yield. ¹² These are the trade-offs a program weighs when deciding where MBI fits relative to ultrasound and MRI. ³

MBI also produces information beyond lesion detection. Background parenchymal uptake, the normal-tissue signal on MBI, is an independent breast cancer risk factor: in a cohort of nearly 3,000 women, elevated BPU was associated with more than double the breast cancer risk, with the strongest signal in postmenopausal women with dense breasts. ⁶ That points toward MBI contributing not just to detection but to risk stratification — identifying which women with dense breasts stand to benefit most from supplemental screening. ⁶

Practical Optimization Tips

1. Use the reduced-dose protocol and verify the activity

Adopt the low-dose administered activity (about 240–300 MBq Tc-99m sestamibi) validated for screening rather than legacy high-activity techniques. Confirm every administered activity against a QC'd dose calibrator — the dose reduction only holds if the measured activity is accurate. See our guide to dose calibrator quality control. ¹⁵

2. Use the CZT-optimized energy window

Reduced-dose MBI depends on an energy acceptance window optimized for the CZT detector, not a generic symmetric photopeak window — the optimized window recaptures the detector's low-energy tail to maximize count sensitivity at the reduced administered activity. Verify the window against the measured energy spectrum and the system vendor's low-dose specification. ⁵¹²

3. Standardize positioning and compression

Use light compression and mammography-analogous craniocaudal and mediolateral oblique views so that MBI findings can be correlated with mammography. Consistent positioning improves lesion localization and reduces motion during the multi-minute acquisitions. ⁴

4. Build a real QC program

Treat the MBI camera like any gamma camera: routine energy-peak and window checks, uniformity, spatial resolution, sensitivity, and count-rate performance, with acceptance testing at installation. Uniformity and resolution drift directly degrade small-lesion detectability. Our overview of gamma camera uniformity QC covers the shared methodology. ⁴

5. Counsel patients on dose and yield honestly

The reduced-dose protocol brings the exam into a defensible range for supplemental screening, but MBI still carries a small radiation dose and a real increase in recalls and benign biopsies. Programs should frame the added yield against those costs. ¹²

Common pitfalls to avoid

Running legacy high-activity protocols. The dose reduction is the reason MBI is screening-acceptable; do not undo it.
Using an over-wide energy window. It wastes the CZT scatter-rejection advantage.
Neglecting dose-calibrator QC. An inaccurate calibrator undermines both dose control and image quality.
Skipping detector uniformity checks. Non-uniformity mimics or masks focal uptake.
Treating MBI as a mammography replacement. It is a supplement, not a substitute. ¹³⁴

Regulatory Considerations

MBI sits under materials regulation, not the mammography (MQSA) framework, because it uses byproduct material and a gamma camera rather than an X-ray machine. The distinction matters for how a program is licensed and inspected.

Key frameworks:

10 CFR Part 35 — Medical Use of Byproduct Material. Tc-99m sestamibi administration falls under medical-use licensing, authorized-user requirements, and written procedures. ⁷
10 CFR Part 20 — Standards for Protection Against Radiation. Occupational and public dose limits, and ALARA, apply to handling and administering the tracer. ⁸
Agreement State programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, New York, New Jersey, and Pennsylvania are NRC Agreement States that license medical use under their own rules — in Florida, under Chapter 64E-5, Parts II and III, for radioactive material — while Washington DC and Delaware are regulated directly by the NRC. ⁷⁸
MQSA and breast-density notification. MBI is not regulated under MQSA (21 CFR Part 900), which governs mammography equipment and personnel. However, the FDA's breast-density reporting requirement — under which mammography reports must inform patients about dense breast tissue — shapes the clinical conversations in which supplemental modalities such as MBI are considered. ⁹
ACR guidance and clinical validation. The ACR practice parameter for the performance of molecular breast imaging defines personnel qualifications, technique, dosimetry, and QC expectations, and dedicated dual-head gamma-camera systems have been validated for small-lesion detection in the peer-reviewed literature. ¹⁰¹¹

A qualified medical physicist establishes the QC program, verifies detector performance and administered activity, and supports the radiation safety program under the facility's radioactive material license. Coordinate this with radioactive material license support and RSO consulting when a program is new or expanding.

Frequently Asked Questions (FAQs)

What is molecular breast imaging (MBI)?

MBI is a functional nuclear medicine exam that detects breast cancer by imaging the preferential uptake of Tc-99m sestamibi in tumor tissue, using a dedicated small-field-of-view gamma camera with the breast lightly compressed. Because it images metabolism rather than anatomy, it is not degraded by dense fibroglandular tissue.

Why is a CZT detector used for MBI?

Cadmium zinc telluride is a direct-conversion semiconductor detector that converts gamma rays straight into an electrical signal, giving better energy resolution and a compact pixelated design than a NaI(Tl) Anger camera. Better energy resolution improves scatter rejection, and the small pixel size supports the resolution needed to detect sub-centimeter lesions.

How much radiation does an MBI exam involve?

Modern low-dose MBI uses about 240–300 MBq of Tc-99m sestamibi, corresponding to an effective dose on the order of about 2–3 mSv. Early systems used two to three times more activity; detector and collimator optimization allowed the reduction to a range considered acceptable for supplemental screening.

Does MBI help in dense breasts?

Yes. Adding MBI to screening mammography substantially increases cancer detection in dense breasts — a reported supplemental yield of about 8.8 additional cancers per 1,000 women screened in one large study — because functional uptake is not masked by dense tissue.

Is MBI the same as breast-specific gamma imaging?

They are closely related; both use Tc-99m sestamibi and a dedicated gamma camera. MBI most commonly refers to dual-head direct-conversion CZT systems developed for reduced-dose imaging, while breast-specific gamma imaging historically referred to single-head systems. The clinical principle is the same.

What quality control does an MBI system need?

Routine gamma-camera QC: energy-peak and window verification, uniformity, spatial resolution, sensitivity, and count-rate checks, plus dose-calibrator QC for administered activity. A qualified medical physicist establishes and reviews the program.

Who regulates MBI?

The Tc-99m is byproduct material regulated by the NRC under 10 CFR Part 35 for medical use and 10 CFR Part 20 for radiation protection, or by the equivalent Agreement State program. The gamma camera is not an X-ray machine, so MBI is not under MQSA.

Key Takeaways

MBI images function, not anatomy. Tumor uptake of Tc-99m sestamibi is largely independent of breast density. ¹⁴
CZT direct-conversion detectors are the enabling technology. Better energy resolution and compact pixelated geometry improve scatter rejection and small-lesion detection. ⁴⁵
Optimized collimation enabled dose reduction. Sensitivity gains of ~1.5–3.2× allowed a proportional drop in administered activity to about 300 MBq (~2.4 mSv effective dose). ¹⁵
Supplemental yield in dense breasts is substantial. About 8.8 additional cancers per 1,000 women, at the cost of more recalls and biopsies. ¹²
Background parenchymal uptake adds risk information. Elevated BPU is an independent breast cancer risk factor. ⁶
It is a materials-regulated exam. 10 CFR Parts 35 and 20 (or Agreement State equivalents), not MQSA. ⁷⁸

Conclusion

Molecular breast imaging is a clear example of physics turning a promising idea into a usable clinical tool. The concept — imaging tumor metabolism to see through dense tissue — was sound decades ago, but MBI only became a defensible supplemental screening exam once direct-conversion CZT detectors and geometry-specific collimation drove the administered activity down to a screening-acceptable dose. The payoff is real: meaningful additional cancer detection in exactly the women mammography serves least well. Realizing that payoff safely depends on the same physics discipline that made it possible — accurate dose control, optimized energy windows, and a rigorous QC program overseen by a qualified medical physicist. ¹⁴⁵

How DRPS Can Help

Diagnostic Radiation Physics Services supports dedicated nuclear-imaging and MBI programs with acceptance testing, gamma-camera QC program design, detector performance verification, administered-activity and dose review, and radiation safety support under the facility's radioactive material license — all delivered by board-certified medical physicists through our PET/CT and nuclear medicine physics and mammography physics (MQSA) services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong MBI program pairs a genuinely useful exam with the dose control and quality assurance that keep it trustworthy.

Related Resources

References

Rhodes DJ, Hruska CB, Conners AL, et al. Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. AJR Am J Roentgenol. 2015;204(2):241-251. doi:10.2214/AJR.14.13357. doi.org
Hruska CB, Conners AL, Jones KN, et al. Diagnostic workup and costs of a single supplemental molecular breast imaging screen of mammographically dense breasts. AJR Am J Roentgenol. 2015;204(6):1345-1353. doi:10.2214/AJR.14.13306. doi.org
Narayanan D, Berg WA. Dedicated breast gamma camera imaging and breast PET: current status and future directions. PET Clin. 2018;13(3):363-381. doi:10.1016/j.cpet.2018.02.008. doi.org
Hruska CB, O'Connor MK. Nuclear imaging of the breast: translating achievements in instrumentation into clinical use. Med Phys. 2013;40(5):050901. doi:10.1118/1.4802733. doi.org
Weinmann AL, Hruska CB, O'Connor MK. Design of optimal collimation for dedicated molecular breast imaging systems. Med Phys. 2009;36(3):845-856. doi:10.1118/1.3077119. doi.org
Hruska CB, Geske JR, Conners AL, et al. Background parenchymal uptake on molecular breast imaging and breast cancer risk: a cohort study. AJR Am J Roentgenol. 2021;216(5):1193-1204. doi:10.2214/AJR.20.23854. doi.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
U.S. Food and Drug Administration. Mammography Quality Standards Act regulations, 21 CFR Part 900 (as amended to require breast density reporting). ecfr.gov
American College of Radiology. ACR Practice Parameter for the Performance of Molecular Breast Imaging (MBI) Using a Dedicated Gamma Camera. acr.org
Hruska CB, Phillips SW, Whaley DH, Rhodes DJ, O'Connor MK. Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. AJR Am J Roentgenol. 2008;191(6):1805-1815. doi:10.2214/AJR.07.3693. doi.org
Hruska CB, Weinmann AL, Tello Skjerseth CM, et al. Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera. Part II. Evaluation in patients. Med Phys. 2012;39(6):3476-3483. doi:10.1118/1.4719959. doi.org